Successful renal transplantation with desensitization in highly sensitized patients: A single center experience

Journal of Korean Medical Science

Volumn 24, Issue SUPPL.1, 2009, Pages

  Yoon, Hye Eun ^a   Hyoung, Bok Jin ^a   Hwang, Hyeon Seok ^a   Lee, So Young ^a   Jeon, Youn Joo ^a   Song, Joon Chang ^a   Oh, Eun Jee ^a   Park, Sun Cheol ^a   Choi, Bum Soon ^a   Moon, In Sung ^a   Kim, Yong Soo ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Desensitization; Immunoglobulins, intravenous; Plasmapheresis, kidney transplantation; Rituximab

Indexed keywords

ALLOANTIBODY; CD20 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; ARTICLE; BIOSYNTHESIS; CHEMISTRY; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; IMMUNOPHENOTYPING; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 62449189714     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.S1.S148     Document Type: Article

References (26)

1. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-95.
2. Stegall MD, Gloor J, Winters JL, Moore SB, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-51.
3. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2: 758-60.
4. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459-66.
5. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76: 1519-25.
6. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6: 2384-90.
7. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, Hunter J, Farney A, Philosophe B, Colonna J, Jarrell BE, Bartlett ST. A high panel-reactive antibody rescue protocol for crossmatch- positive live donor kidney transplants. Transplantation 2000; 70: 1531-36.
8. Jordan SC, Tyan D, Stablein D, Mcintosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-62.
9. Magee CC, Mah H, Tinckam K, Wood I, Ji F, Powelson J. Successful living donor kidney transplantation across HLA and ABO incompatibilities. Nephrol Dial Transplant. 2007; 22: 602-4.
10. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, Larson TS, Griffen MD, Textor SC, Velosa JA, Schwab TR, Fix LA, Stegall MD. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-23.
11. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen con sisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002; 74: 1207-10.
12. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-22.
13. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005; 5: 145-8.
14. Yang CW, Oh EJ, Lee SB, Moon IS, Kim DG, Choi BS, Park SC, Choi YJ, Park YJ, Han K. Detection of donor-specific anti-HLA class I and II antibodies using antibody monitoring system. Transplant Proc 2006; 38: 2803-6.
15. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody- mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-14.
16. Book BK, Agarwal A, Milgrom AB, Bearden CM, Sidner RA, Higgins NG, Pescovitz MD. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 2005; 37: 640-42.
17. Opelz G. Collaborative transplant study-10-year report. Transplat Proc 1992; 24: 2342-55.
18. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplantation 2004; 8: 535-42.
19. Kotb M, Russell WC, Hathaway DK, Gaber LW, Gaber AO. The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Clin Transplant 1999; 13: 83-9.
20. Lazda VA. Identification of patients at risks for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch. Transplantation 1994; 57: 964-9.
21. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84: S4-7.
22. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-8.
23. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation 2007; 84: S33-6.
24. Matignon M, Tagnaouti M, Audard V, Dahan K, Lang P, Grimbert P. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody- mediated rejection in three crossmatch-positive renal transplant recipients. Transplant Proc 2007; 39: 2565-7.
25. Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant 2006; 20 (Suppl 17): 7-12.
26. Choi BS, Shin MJ, Shin SJ, Kim YS, Choi YJ, Kim YS, Moon IS, Kim SY, Koh YB, Bang BK, Yang CW. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354-60.